Company intelligence / Profile preview
Oblenio Bio
Oakland, California, United Statesobleniobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oblenio Bio is engaged in developing LBL-051, a first-in-class tri-specific T-cell engager antibody targeting CD19, BCMA, and CD3 for the treatment of autoimmune diseases. The company is newly formed and preparing to enter clinical studies. Its approach, based on dual B cell targeting, aims to deliver a more complete and durable immune reset compared to therapies targeting CD19 or BCMA alone. Clinical results for the specific asset (LBL-051) have not yet been reported as it is being advanced toward first-in-human studies.
- Therapeutic areas
- Immunology
- Modalities
- AntibodyT cell engagerTri-specific antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Aditum BioLeads Biolabs
Beyond the preview
Go deeper on Oblenio Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oblenio Bio.